| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -40,371 | -23,171 |
| Share-based compensation expense | 2,809 | 1,893 |
| Depreciation and amortization | 523 | 344 |
| Accretion of discounts on available-for-sale investments | 706 | 537 |
| Loss on disposal of property and equipment | -34 | -34 |
| Accounts receivable, net | -772 | -789 |
| Prepaid expenses and other assets | 5,335 | 3,524 |
| Other non-current assets | 6 | 7 |
| Accounts payable | 1,652 | 1,952 |
| Accrued liabilities | 1,130 | 131 |
| Contract liabilities | 1 | 0 |
| Operating lease liabilities | 55 | 56 |
| Contract assets | - | 0 |
| Other non-current liabilities | -514 | -510 |
| Net cash used in operating activities | -39,956 | -22,550 |
| Purchases of short-term investments | 30,470 | 30,470 |
| Proceeds from maturities and sales of short-term investments | 29,720 | 15,340 |
| Purchases of property and equipment | 418 | 384 |
| Proceeds from sale of property and equipment | 2 | 2 |
| Net cash (used in) provided by investing activities | -1,166 | -15,512 |
| Proceeds from purchases under the espp | 143 | 143 |
| Proceeds from exercise of stock options | 235 | 20 |
| Net cash provided by financing activities | 378 | 163 |
| Effect of exchange rate changes on cash and cash equivalents | 357 | 299 |
| Net decrease in cash and cash equivalents | -40,387 | -37,600 |
| Cash and cash equivalents at beginning of period | 78,232 | - |
| Cash and cash equivalents at end of period | 37,845 | - |
Connect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Ltd (CNTB)